1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.04
D/E ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.14. Benjamin Graham would praise this conservative approach, but check if excess equity dilutes returns.
-7.17
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.68. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-23.91
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
7.61
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.19. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
46.74%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.84%. Michael Burry would check for aggressive accounting and hidden risks.
